JAMA:局限性前列腺癌患者应如何选择适合自己的手术方式?

2017-03-24 MedSci MedSci原创

局限性前列腺癌的患者需要在不良反应各异的治疗策略中作出决定。近期,一项发表在权威杂志JAMA上的研究旨在比较根治性前列腺切除术、外放射治疗、近距离放射治疗与主动检测的生活质量(QOL)。此项研究为前瞻性队列研究,纳入了自2011年1月至2013年6月北卡罗来纳州中央癌症登记处的1141名(合格男性参与57%)新诊断的前列腺癌人群。从诊断到入院的中位时间为5周,所有男性在接受治疗前均已获得书面知情同

局限性前列腺癌的患者需要在不良反应各异的治疗策略中作出决定。


近期,一项发表在权威杂志JAMA上的研究旨在比较根治性前列腺切除术、外放射治疗、近距离放射治疗与主动检测的生活质量(QOL)。

此项研究为前瞻性队列研究,纳入了自2011年1月至2013年6月北卡罗来纳州中央癌症登记处的1141名(合格男性参与57%)新诊断的前列腺癌人群。从诊断到入院的中位时间为5周,所有男性在接受治疗前均已获得书面知情同意书。分析的最终后续日期为2015年9月9日。

此项研究使用经验证的前列腺癌症状指数评估在基线(预处理)和治疗后3、12和24个月的生活质量。该评价工具包含4个领域-性功能障碍、尿阻塞和刺激、尿失禁和肠道问题-每个评分从0(无功能障碍)至100(最大功能障碍)。

此项研究结果显示:共有1141名男性患者入组。其中314人进行积极监测(27.5%),469例根治性前列腺切除术(41.1%),249例外放射治疗(21.8%)和109例近距离放射治疗(9.6%)。
倾向加权后,中位数年龄为66〜67岁,77%〜80%为白人。跨组的性功能障碍倾向加权平均基线得分为41.8至46.4,尿阻塞和刺激为20.8至22.8,尿失禁为9.7至10.5,肠道问题为5.7至6.1。
与主动监测相比,接受根治性前列腺切除术(36.2 [95%CI,30.4-42.0]),外侧放射治疗(13.9 [95%CI,6.7-21.2])和近距离放射治疗(17.1 [95%CI,7.8-26.6])的患者在3个月后的平均性功能更差。

与3个月的主动监测相比,更糟糕的尿失禁与根治性前列腺切除术相关(33.6 [95%CI,27.8-39.2]);外放射治疗(11.7 [95%CI,8.7-14.8])和近距离放射治疗(20.5 [95%CI,15.1-25.9])引起的尿路梗阻和刺激急性恶化;外放射治疗(4.9 [95%CI,2.4-7.4])的肠道症状更恶化。到24个月时,治疗组与主动监测的平均得分在大多数领域没有显着差异。

此项研究表明:在局限性前列腺癌的男性患者中,每个治疗策略与不同的不良反应模式相关。这些发现可用于纳入个人喜好的治疗方式的选择。

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1651156, encodeId=c8d6165115623, content=<a href='/topic/show?id=60d45443e91' target=_blank style='color:#2F92EE;'>#手术方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54437, encryptionId=60d45443e91, topicName=手术方式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=916a24134794, createdName=dinorsor532, createdTime=Sun Dec 17 04:19:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924019, encodeId=121319240194f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Mon Nov 27 20:19:00 CST 2017, time=2017-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460462, encodeId=c2941460462ab, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sun Mar 26 11:19:00 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182508, encodeId=a36c18250832, content=学习,分享!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Mar 25 00:10:42 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182475, encodeId=f8041824e573, content=在局限性前列腺癌的男性患者中,每个治疗策略与不同的不良反应模式相关。, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd301464769, createdName=Albert Wu, createdTime=Fri Mar 24 21:53:13 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182468, encodeId=33a718246846, content=签到学习了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Mar 24 20:39:03 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1651156, encodeId=c8d6165115623, content=<a href='/topic/show?id=60d45443e91' target=_blank style='color:#2F92EE;'>#手术方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54437, encryptionId=60d45443e91, topicName=手术方式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=916a24134794, createdName=dinorsor532, createdTime=Sun Dec 17 04:19:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924019, encodeId=121319240194f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Mon Nov 27 20:19:00 CST 2017, time=2017-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460462, encodeId=c2941460462ab, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sun Mar 26 11:19:00 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182508, encodeId=a36c18250832, content=学习,分享!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Mar 25 00:10:42 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182475, encodeId=f8041824e573, content=在局限性前列腺癌的男性患者中,每个治疗策略与不同的不良反应模式相关。, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd301464769, createdName=Albert Wu, createdTime=Fri Mar 24 21:53:13 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182468, encodeId=33a718246846, content=签到学习了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Mar 24 20:39:03 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1651156, encodeId=c8d6165115623, content=<a href='/topic/show?id=60d45443e91' target=_blank style='color:#2F92EE;'>#手术方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54437, encryptionId=60d45443e91, topicName=手术方式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=916a24134794, createdName=dinorsor532, createdTime=Sun Dec 17 04:19:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924019, encodeId=121319240194f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Mon Nov 27 20:19:00 CST 2017, time=2017-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460462, encodeId=c2941460462ab, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sun Mar 26 11:19:00 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182508, encodeId=a36c18250832, content=学习,分享!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Mar 25 00:10:42 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182475, encodeId=f8041824e573, content=在局限性前列腺癌的男性患者中,每个治疗策略与不同的不良反应模式相关。, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd301464769, createdName=Albert Wu, createdTime=Fri Mar 24 21:53:13 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182468, encodeId=33a718246846, content=签到学习了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Mar 24 20:39:03 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1651156, encodeId=c8d6165115623, content=<a href='/topic/show?id=60d45443e91' target=_blank style='color:#2F92EE;'>#手术方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54437, encryptionId=60d45443e91, topicName=手术方式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=916a24134794, createdName=dinorsor532, createdTime=Sun Dec 17 04:19:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924019, encodeId=121319240194f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Mon Nov 27 20:19:00 CST 2017, time=2017-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460462, encodeId=c2941460462ab, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sun Mar 26 11:19:00 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182508, encodeId=a36c18250832, content=学习,分享!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Mar 25 00:10:42 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182475, encodeId=f8041824e573, content=在局限性前列腺癌的男性患者中,每个治疗策略与不同的不良反应模式相关。, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd301464769, createdName=Albert Wu, createdTime=Fri Mar 24 21:53:13 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182468, encodeId=33a718246846, content=签到学习了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Mar 24 20:39:03 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
    2017-03-25 明天会更好!

    学习,分享!!!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1651156, encodeId=c8d6165115623, content=<a href='/topic/show?id=60d45443e91' target=_blank style='color:#2F92EE;'>#手术方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54437, encryptionId=60d45443e91, topicName=手术方式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=916a24134794, createdName=dinorsor532, createdTime=Sun Dec 17 04:19:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924019, encodeId=121319240194f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Mon Nov 27 20:19:00 CST 2017, time=2017-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460462, encodeId=c2941460462ab, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sun Mar 26 11:19:00 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182508, encodeId=a36c18250832, content=学习,分享!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Mar 25 00:10:42 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182475, encodeId=f8041824e573, content=在局限性前列腺癌的男性患者中,每个治疗策略与不同的不良反应模式相关。, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd301464769, createdName=Albert Wu, createdTime=Fri Mar 24 21:53:13 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182468, encodeId=33a718246846, content=签到学习了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Mar 24 20:39:03 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
    2017-03-24 Albert Wu

    在局限性前列腺癌的男性患者中,每个治疗策略与不同的不良反应模式相关。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1651156, encodeId=c8d6165115623, content=<a href='/topic/show?id=60d45443e91' target=_blank style='color:#2F92EE;'>#手术方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54437, encryptionId=60d45443e91, topicName=手术方式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=916a24134794, createdName=dinorsor532, createdTime=Sun Dec 17 04:19:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924019, encodeId=121319240194f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Mon Nov 27 20:19:00 CST 2017, time=2017-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460462, encodeId=c2941460462ab, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sun Mar 26 11:19:00 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182508, encodeId=a36c18250832, content=学习,分享!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Mar 25 00:10:42 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182475, encodeId=f8041824e573, content=在局限性前列腺癌的男性患者中,每个治疗策略与不同的不良反应模式相关。, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd301464769, createdName=Albert Wu, createdTime=Fri Mar 24 21:53:13 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182468, encodeId=33a718246846, content=签到学习了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Mar 24 20:39:03 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
    2017-03-24 Chongyang Zhang

    签到学习了很多

    0

相关资讯

Cancer:前列腺癌病人为什么向泌尿科医师寻求补充性意见以及和治疗的联系?

癌症病人通常在开始治疗前被鼓励去获得一些第二诊断意见,但是患有局部性前列腺癌的哪些患者寻求第二诊断意见及原因,以及与治疗和医疗品质的关系却所知甚少。来自美国费城的一项调查初步解释了这个问题。研究人员调查了2012-2014年间患有局部性前列腺癌的患者,并询问他们是否从泌尿科医师那里获得第二诊断意见和原因,并利用多元逻辑回归模型去评估第二诊断意见与确定前列腺癌治疗、医疗品质的感受之间的关系。总共有2

Cancer:前列腺癌病人为什么向泌尿科医师寻求第二诊断意见以及和治疗的联系?

癌症病人通常在开始治疗前被鼓励去获得一些第二诊断意见,但是患有局部性前列腺癌的哪些患者寻求第二诊断意见及原因,以及与治疗和医疗品质的关系却所知甚少。来自美国费城的一项调查初步解释了这个问题。研究人员调查了2012-2014年间患有局部性前列腺癌的患者,并询问他们是否从泌尿科医师那里获得第二诊断意见和原因,并利用多元逻辑回归模型去评估第二诊断意见与确定前列腺癌治疗、医疗品质的感受之间的关系。总共有2

J CLIN INVEST:AKT介导的组蛋白甲基转移酶WHSC1稳态促进前列腺癌转移

来自中科院上海健康科学研究所的研究人员报道了一项关于前列腺癌转移的新机制的研究,研究显示表观遗传调节因子WHSC1和关键细胞内信号分子AKT,RICTOR和Rac1之间的关键性联系。 相关研究成果刊登于国际权威杂志Journal of clinical investigation上。

Nature:福音!组合免疫疗法治疗雄激素抵抗性前列腺癌可能有效!

用雄激素阻断治疗晚期前列腺癌患者的一部分患者群体往往经历癌症的复发,病情往往发展到致死的转移性雄激素抵抗前列腺癌(mCRPC)。在一个患有各种癌症的病例群体中,利用细胞毒性T淋巴细胞相关蛋白-4抗体或者程序性细胞死亡-1/程序性细胞死亡-1-配体-1(PD1/PD-L1)抗体的免疫检查点阻断疗法能够产生持久的治疗反应。然而,mCRPC却表现出对免疫检查点阻断疗法不断更新的抗性,这种现象促使了研究人

Int J Cancer:乳制品摄入量与前列腺癌患者存活率有关!

之前有研究指出,乳制品的摄入与增加患晚期前列腺癌风险有关。在美国,对两个群体的研究表明了随着高脂肪奶制品的摄入,前列腺癌引起死亡患者的数目也随之增加。最近,研究人员在一个瑞典的乳制品高消费病人群体中,调查了乳制品和相关营养物质的摄入是否与前列腺癌的发展有关。研究人员跟踪调查了525个男性初诊为前列腺癌患者,诊断日期在1989年到1994年。 在2011年2月,他们鉴定和确认了222例前列腺癌死亡患

JAMA:局部前列腺癌治疗的3种方法哪个更好?

了解目前局部前列腺癌治疗方法的不良影响可以为共同决策提供相关信息。近期,一项发表在权威杂志JAMA上的研究旨在比较与根治性前列腺切除术相比,外部束放射治疗(EBRT)和主动监测相关的功能结果和不良反应。此项研究是前瞻性、基于人群的队列研究,收集了2011-2012年诊断为临床cT1-2期的2550名男性(≤80岁)局限性前列腺癌,且前列腺特异性抗原水平低于50 ng / mL,并在6个月内诊断的患